Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilié, Carl M. Gay, Lauren A. Byers, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 13, pp. 3759-3771
Open Access | Times Cited: 289

Showing 1-25 of 289 citing articles:

PARP and PARG inhibitors in cancer treatment
Dea Slade
Genes & Development (2020) Vol. 34, Iss. 5-6, pp. 360-394
Open Access | Times Cited: 515
Poly(ADP-ribose) polymerase inhibition: past, present and future
Nicola J. Curtin, Csaba Szabó
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 10, pp. 711-736
Closed Access | Times Cited: 396
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
Rowan Miller, Alexandra Léary, Clare L. Scott, et al.
Annals of Oncology (2020) Vol. 31, Iss. 12, pp. 1606-1622
Open Access | Times Cited: 356
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 12, pp. 773-791
Closed Access | Times Cited: 342
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
Jacqueline H. L. Fok, Antonio Ramos‐Montoya, Mercedes Vázquez–Chantada, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 271
Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
Steven Coats, Marna Williams, Benjamin Kebble, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 18, pp. 5441-5448
Open Access | Times Cited: 254
Molecular targeted therapy for anticancer treatment
Hye‐Young Min, Ho‐Young Lee
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1670-1694
Open Access | Times Cited: 239
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency
Ke Cong, Min Peng, Arne Nedergaard Kousholt, et al.
Molecular Cell (2021) Vol. 81, Iss. 15, pp. 3128-3144.e7
Open Access | Times Cited: 234
53BP1: a DSB escort
Zachary Mirman, Titia de Lange
Genes & Development (2020) Vol. 34, Iss. 1-2, pp. 7-23
Open Access | Times Cited: 209
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
Peter Horak, Christoph Heining, Simon Kreutzfeldt, et al.
Cancer Discovery (2021) Vol. 11, Iss. 11, pp. 2780-2795
Open Access | Times Cited: 200
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud, Antoîne Italiano
Cancers (2020) Vol. 12, Iss. 6, pp. 1502-1502
Open Access | Times Cited: 180
Harnessing DNA Double-Strand Break Repair for Cancer Treatment
Anika Trenner, Alessandro A. Sartori
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 164
Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells
Stephanie Tirman, Annabel Quinet, Matthew Wood, et al.
Molecular Cell (2021) Vol. 81, Iss. 19, pp. 4026-4040.e8
Open Access | Times Cited: 128
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
Dae-Seok Kim, Cristel V. Camacho, W. Lee Kraus
Experimental & Molecular Medicine (2021) Vol. 53, Iss. 1, pp. 42-51
Open Access | Times Cited: 126
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Giuditta Illuzzi, Anna D. Staniszewska, Sonja J. Gill, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 21, pp. 4724-4736
Open Access | Times Cited: 95
Inhibitors of PARP: Number crunching and structure gazing
Johannes Rudolph, Karen Jung, Karolin Luger
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 11
Open Access | Times Cited: 83
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Karim Fizazi, Arun Azad, Nobuaki Matsubara, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 257-264
Open Access | Times Cited: 59
Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability
Jenna Whalen, Jillian Earley, Christi Wisniewski, et al.
Nature Cancer (2025)
Closed Access | Times Cited: 1
Prospects for combining immune checkpoint blockade with PARP inhibition
Anping Li, Ming Yi, Shuang Qin, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 119
Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
Ádám Póti, Hella Gyergyák, Eszter Németh, et al.
Genome biology (2019) Vol. 20, Iss. 1
Open Access | Times Cited: 106
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers
Timothy A. Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Cancer Discovery (2020) Vol. 10, Iss. 10, pp. 1528-1543
Open Access | Times Cited: 104
Advances and perspectives of PARP inhibitors
Ming Yi, Bing Dong, Shuang Qin, et al.
Experimental Hematology and Oncology (2019) Vol. 8, Iss. 1
Open Access | Times Cited: 103
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
Stefania Cocco, Michela Piezzo, Alessandra Calabrese, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 13, pp. 4579-4579
Open Access | Times Cited: 96
ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer
Zhe Tang, Patrick G. Pilié, Chuandong Geng, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 17, pp. 4898-4909
Open Access | Times Cited: 91
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
Jeffrey W. Johannes, Amber Balazs, Derek Barratt, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 19, pp. 14498-14512
Closed Access | Times Cited: 89
Page 1 - Next Page

Scroll to top